Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, selective small-molecule inhibitor of ROCK1 and ROCK2, with IC₅₀ values of 140 nM and a K_i of 300 nM, respectively, and shows >200-fold selectivity against off-target kinases such as PKC and PAK (Ren et al. 2025). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression, making it essential for studies in cytoskeletal dynamics and cell proliferation. Y-27632 enhances stem cell viability and is frequently used to prevent dissociation-induced apoptosis. In vivo, it suppresses tumor invasion and metastasis in murine models, highlighting its translational relevance. Storage and solubility parameters are well-established, enabling reproducible experimental workflows (APExBIO).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases central to cytoskeletal organization, cell adhesion, migration, and proliferation. Activation of the RhoA/ROCK pathway leads to phosphorylation of myosin light chain 2 (MLC2), resulting in actomyosin contraction and stress fiber assembly. This signaling axis regulates tight junction integrity, cellular morphology, and cell cycle transitions from G1 to S phase (Ren et al. 2025). Dysregulation is implicated in cancer metastasis, fibrosis, and neurodegeneration. Selective inhibition of ROCK1/2 enables precise dissection of these pathways in vitro and in vivo. Y-27632 dihydrochloride, as provided by APExBIO, offers nanomolar potency and high kinase selectivity, making it an indispensable reagent for probing Rho/ROCK signaling in cell biology, cancer, and stem cell research (APExBIO product page).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride specifically targets the ATP-binding catalytic domains of ROCK1 and ROCK2, competitively inhibiting their kinase activity. By blocking phosphorylation of downstream substrates such as MLC2, LIM kinase, and cofilin, Y-27632 disrupts actomyosin contractility and stress fiber formation. Inhibition of ROCK-driven contractility leads to loss of focal adhesions and relaxation of cellular tension (Ren et al. 2025). This in turn modulates cell shape, migration, and proliferation. Notably, Y-27632 does not significantly inhibit closely related kinases (e.g., PKC, MLCK, or PAK) at concentrations below 10 μM, ensuring pathway specificity. In cell models, treatment with 10 μM Y-27632 induces rapid loss of stress fibers within 30–60 minutes at 37°C. In stem cell cultures, Y-27632 prevents dissociation-induced apoptosis (anoikis) by maintaining cytoskeletal integrity and cell-cell adhesion.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM under standard kinase assay conditions (Ren et al. 2025).
• Demonstrates >200-fold selectivity against PKC, cAMP-dependent protein kinase, MLCK, and PAK, ensuring minimal off-target effects at working concentrations (APExBIO).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (1–20 μM, 24–72 h) (Ren et al. 2025).
• In vivo, Y-27632 decreases tumor invasion and metastasis in mouse models, as evidenced by reduced pathological structures and lower metastatic burden (Ren et al. 2025).
• Soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C; warming to 37°C or ultrasonic bath enhances dissolution (APExBIO).
• Stock solutions stable for several months below –20°C; long-term storage of aqueous solutions not recommended due to hydrolysis risk (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is employed in diverse experimental contexts:

• Stem cell research: Enhances survival of dissociated human embryonic stem cells and induced pluripotent stem cells by inhibiting apoptosis pathways (Ren et al. 2025).
• Cancer biology: Suppresses tumor cell invasion and metastasis by disrupting cytoskeletal remodeling and cell motility (Ren et al. 2025).
• Barrier function and tight junction studies: Used to dissect the role of ROCK in tight junction integrity, as demonstrated in viral infection models (Ren et al. 2025).
• Cell proliferation assays: Enables functional studies of Rho/ROCK signaling in cell cycle transitions and cytokinesis.
• Precision modulation of cytoskeletal dynamics: Facilitates reproducible manipulation of actomyosin contractility in developmental biology and tissue engineering.

For a deeper mechanistic review, see Strategic Modulation of Rho/ROCK Signaling: Y-27632 Dihydrochloride, which provides advanced insights into microfabrication-enabled workflows; this article updates the context with recent in vivo cancer benchmarks.

For clinical and translational perspectives, Strategic ROCK Inhibition in Translational Research: Unleashing the Potential of Y-27632 highlights stem cell applications; this article adds detailed solubility and storage parameters for reproducibility.

See Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal Studies for further background; this article extends those findings with evidence from recent peer-reviewed studies.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit RhoA GTPase itself; it acts downstream at ROCK1/2.
• It is not effective against non-ROCK kinases at standard concentrations (≤10 μM).
• Long-term storage of prepared aqueous solutions (>1 week at 4°C) leads to degradation.
• Does not induce pluripotency or differentiation; it enhances survival of stem cells under stress.
• Not a substitute for genetic knockdown/knockout approaches when full pathway ablation is required.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid by APExBIO (SKU: A3008). It should be stored desiccated at 4°C or below. To prepare working solutions, dissolve in DMSO at ≥111.2 mg/mL, ethanol at ≥17.57 mg/mL, or water at ≥52.9 mg/mL at room temperature; warming to 37°C or using an ultrasonic bath can facilitate dissolution. Aliquots are stable for several months at –20°C. For in vitro assays, typical working concentrations range from 1 μM to 20 μM, depending on cell type and endpoint. For in vivo mouse studies, dosing regimens and administration routes should be optimized based on published protocols. Avoid repeated freeze–thaw cycles to maintain compound integrity.

Refer to the Y-27632 dihydrochloride product page at APExBIO for lot-specific data and safety information.

Conclusion & Outlook

Y-27632 dihydrochloride is a benchmark tool for selective inhibition of ROCK1 and ROCK2, with established utility in cytoskeletal, cancer, and stem cell research. Its high selectivity and robust solubility profile support reproducible experimental outcomes. Ongoing research expands its application in disease modeling, regenerative medicine, and anti-metastatic therapy. For comprehensive mechanistic discussions and advanced workflows, see recent reviews and APExBIO resources. Y-27632 remains a critical reagent for dissecting Rho/ROCK signaling in translational and basic science contexts.